Indclav Bid 228 Dry Syrup is a combination antibiotic formulation containing Amoxycillin 200 mg and Clavulanic Acid 28.5 mg per dose, designed for oral suspension. Amoxycillin, a broad-spectrum penicillin antibiotic, inhibits bacterial cell wall synthesis, leading to cell lysis and death, while Clavulanic Acid acts as a beta-lactamase inhibitor, preventing enzymatic degradation of Amoxycillin by resistant bacteria. This synergistic action extends the antimicrobial spectrum against beta-lactamase-producing pathogens. Indclav Bid 228 Dry Syrup is indicated for the treatment of various bacterial infections including respiratory tract infections, otitis media, sinusitis, skin and soft tissue infections, and urinary tract infections caused by susceptible organisms. The dry syrup formulation is particularly suitable for pediatric patients who have difficulty swallowing tablets. Dosage and duration should be determined based on the severity of infection, patient age, and renal function, with administration typically twice daily. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and vomiting, as well as hypersensitivity reactions in penicillin-sensitive individuals. Caution is advised in patients with a history of penicillin allergy or hepatic impairment. Proper reconstitution and adherence to prescribed dosing are essential to ensure therapeutic efficacy and minimize resistance development.